IMM Stock Overview
A clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Immutep Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.34 |
52 Week High | AU$0.48 |
52 Week Low | AU$0.23 |
Beta | 1.9 |
11 Month Change | -21.84% |
3 Month Change | -19.05% |
1 Year Change | 9.68% |
33 Year Change | -29.17% |
5 Year Change | 54.55% |
Change since IPO | -88.67% |
Recent News & Updates
Recent updates
Shareholder Returns
IMM | AU Biotechs | AU Market | |
---|---|---|---|
7D | 15.3% | -1.7% | -2.2% |
1Y | 9.7% | 14.8% | 5.4% |
Return vs Industry: IMM underperformed the Australian Biotechs industry which returned 14.8% over the past year.
Return vs Market: IMM exceeded the Australian Market which returned 5.4% over the past year.
Price Volatility
IMM volatility | |
---|---|
IMM Average Weekly Movement | 12.5% |
Biotechs Industry Average Movement | 12.2% |
Market Average Movement | 8.1% |
10% most volatile stocks in AU Market | 16.4% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: IMM's share price has been volatile over the past 3 months.
Volatility Over Time: IMM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.
Immutep Limited Fundamentals Summary
IMM fundamental statistics | |
---|---|
Market cap | AU$484.35m |
Earnings (TTM) | -AU$40.50m |
Revenue (TTM) | AU$3.93m |
123.2x
P/S Ratio-12.0x
P/E RatioIs IMM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMM income statement (TTM) | |
---|---|
Revenue | AU$3.93m |
Cost of Revenue | AU$37.72m |
Gross Profit | -AU$33.79m |
Other Expenses | AU$6.71m |
Earnings | -AU$40.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.028 |
Gross Margin | -859.57% |
Net Profit Margin | -1,030.32% |
Debt/Equity Ratio | 0.8% |
How did IMM perform over the long term?
See historical performance and comparison